← All trials
NCT05591339
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2023
- Primary completion
- Aug 1, 2026
- Completion date
- Aug 1, 2026
- First posted
- Oct 24, 2022
- Last posted
- Nov 2, 2022
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bandim Health ProjectLead sponsor
- Bandim Health ProjectOverall official - principal investigator
- Hospital of Southwest JutlandOverall official - principal investigator
- Steno Diabetes Center CopenhagenCollaborator
- Steno Diabetes Center CopenhagenOverall official - principal investigator
- University of CoimbraCollaborator
- University of Southern DenmarkCollaborator
- Steno Diabetes Center CopenhagenOfficial
- Bandim Health ProjectOfficial
- Hospital of Southwest JutlandOfficial
- University of CoimbraOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.